MTM1 and liver disorder: The emergence of fatal liver disease as an adverse event in the gene therapy trial for X-linked myotubular myopathy and the finding of intrahepatic cholestasis in untreated patients (8) have raised the question of whether loss of MTM1 itself is associated with liver pathology and, if so, via what mechanism.